A Randomized, Double-Blind, Placebo-Controlled,three arm, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence and Safety of Tacrolimus Ointment, 0.1% (EncubeEthicals Private Limited)with ProtopicÂ® (tacrolimus) ointment, 0.1% (AstellasPharma US, Inc.) in the Treatment of Moderate to SevereAtopic Dermatitis.

Encube Ethicals Private Ltd0 个研究点目标入组 13 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 未知
状态: Other
发起方
入组人数: 13

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Ba/be

入排标准

入选标准

•1.Non Immunocompromised Male or non-pregnant, non-lactating female, 18 years and older at the time of signing the informed consent.
•2.Subjects having confirmed diagnosis of atopic dermatitis for at least 3 months.
•3.Subject with clinical diagnosis of moderate to severeatopic dermatitis that has failed to respond adequately to other topical prescription treatments for atopic dermatitis, or for whom those treatments are not advisable per Investigator.
•4.Subject having an Investigatorâ??s Global Assessments (IGA) of disease severity of at least moderate [a score of 3 (moderate) or 4 (severe)] AND have a minimum SCORAD score of disease severity is >15.
•5.Subject having an affected area of AD involvement of at least 20% Body Surface Area (BSA) at baseline, as defined by the Hanifin and Rajka criteria.
•6.Subject is capable of understanding the purposes and risks of the trial and has given written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
•7.Both male and female subjects of child bearing potential must be practicing adequate contraception (for example total abstinence, intrauterine device, a double-barrier method, oral, transdermal, injected, or implanted non-hormonal or hormonal contraceptive) throughout the studyand female subjects of childbearing potential must not be/likely to be pregnant or lactating and must have a negative serum pregnancy test at screening and negative urine pregnancy test at randomization.
•8.Subject agrees to compliance with the protocol and adheres to the protocol requirements for the entire study period.

排除标准

•1.Subjects with diagnosis of atopic dermatitis for less than 3 months.
•2.Reports active cutaneous bacterial or viral infection in any treatment area at baseline (e.g.,clinically infected atopic dermatitis).
•3.Sunburn, extensive scarring, or pigmented lesion(s) in any treatment area at baseline, which would interfere with evaluations.
•4.History of confounding skin conditions, e.g., psoriasis, rosacea, erythroderma, orichthyosis
•5.Females who are pregnant, lactating or likely to become pregnant during the study.
•6.History or presence of Nethertonâ??s Syndrome, immunological deficiencies or diseases, HIV, diabetes, malignancy, serious active or recurrent infection, clinically significant severe renal insufficiency or severe hepatic disorders.
•7.Use within one month prior to baseline of 1) oral or intravenous corticosteroids, 2) UVA/UVB therapy, 3) PUVA (psoralen plus ultraviolet A) therapy, 4) tanning booths, 5) nonprescription UV light sources, 6) immunomodulators or immunosuppressive therapies, 7) interferon, 8) cytotoxic drugs, 9) Tacrolimus, or 10) Pimecrolimus.
•8.Use within 14 days of baseline of: 1) systemic antibiotics, 2) Calcipotriene or other Vitamin D preparations, or 3) retinoids.
•9.Use within 7 days prior to baseline of: 1) antihistamines, 2) topical antibiotics, 3) topical corticosteroids or 4) other topical drug products.
•10. Use within 24 hours prior to baseline of any topical product (e.g., sunscreens, lotions, creams, emollient, moisturizers) in the areas to be treated.
•11.Known allergy or hypersensitivity to Tacrolimus or any other component of the test product or RLD.
•12.Not willing to minimize or avoid natural and artificial sunlight exposure during treatment.
•13.Subjects with clinically significant unstable medical disorders, life-threatening disease, or current malignancies.
•14.Demonstrates a positive test result for Hepatitis B surface antigen, Hepatitis C antibody or HIV antibody.
•15.Reports simultaneous participation in any other drug trial or participation in any other trial involving investigational medicinal product within 30 days of randomization. However, subjects can be enrolled considering elimination half-life of study drug of last participation and/or pharmacokinetic profile of such drug molecule of last participation and/or other medical judgment (if any) to justify the subjectâ??s participation based on investigator opinion and/or sponsor medical monitor.
•16.Any other condition, that in the investigatorâ??s judgment, might compromise subject safety or affect study results
•17.Abnormal baseline findings considered by the investigator to indicate conditions that might affect study endpoints and/or might increase the risk to the subject or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.
•18.Employees of the Investigator or research centre or their immediate family members

研究者

发起方

Encube Ethicals Private Ltd

相似试验

已完成

1 期

Bioequivalence Study of Pimecrolimus cream in Atopic dermatitis patients

CTRI/2018/11/016271Encube Ethicals Private Ltd588

尚未招募

2 期

Asphelia Trichuris Suis Ova in Moderately Active Crohn's DiseaseCrohn's Disease

ACTRN12608000241336Asphelia Pharmaceuticals Inc.60

进行中（未招募）

1 期

Proof of concept treatment study of orally administered VH4004280 or VH4011499 in HIV-1 infected adultsHIV Infections

CTIS2023-505350-18-00Viiv Healthcare UK Limited43

已完成

不适用

To evaluate the Bio equivalence of two Tacrolimus 0.03% topical Ointment formulations in adult patients with moderate to Severe Atopic Dermatitis

CTRI/2016/03/006735Intas Pharmaceuticals Ltd346

招募中

3 期

A study to evaluate effectiveness of Tacrolimus 0.1% Topical Ointment in the patients of the allergic dermatitis.

CTRI/2012/05/002636Accord Healthcare Ltd650